Narrowing the Gap Between Diagnosis of Psoriasis and Psoriatic Arthritis
The causes for, and ways to improve, the diagnostic delays in patients with psoriasis who progress to psoriatic arthritis are discussed.
Psoriasis
PSORIASIS
FEATURE ARTICLE
LATEST NEWS
First Interchangeable Biosimilar to Humira Gets FDA Approval
The interchangeable biosimilar product may be substituted for the reference product by a pharmacist.
Travel Restrictions Hinder Bimekizumab BLA Review
Bimekizumab is an investigational humanized monoclonal IgG1 antibody that selectively inhibits both interleukin (IL)-17A and IL-17F.
Cal/BD Foam Flare Treatment Successful for Psoriasis
The effect of long-term proactive or reactive treatment of psoriasis with calcipotriene and betamethasone dipropionate (Cal/BD) foam via patient-reported outcomes is reported.
Infection Risk Does Not Seem to Differ Among Biologics for Psoriasis
Among biologics used for the treatment of psoriasis, there do not appear to be differential risks for serious infection or respiratory tract infection.
Effect of Tofacitinib on Quality of Life Mediated by Itch in Patients With Psoriatic Arthritis
The extent to which tofacitinib affects the health-related quality of life in patients with psoriatic arthritis was studied, based on improvements in itch.
Body Surface Area of Psoriasis Strongly Predicts Psoriatic Arthritis Risk
Researchers examined the association between psoriasis severity and the development of psoriatic arthritis.
Use of Antihypertensive Drugs May Increase Risk for Psoriasis
Antihypertensive drugs are associated with an increased risk for psoriasis.
Risankizumab an Option for Long-Term Psoriasis Treatment
An extension analysis of a study of patients with psoriasis treated with risankizumab is reported.
Brodalumab Effective for Psoriasis Treatment After Other IL-17 RA Failure
The short- and long-term effectiveness of brodalumab in patients with psoriasis in whom treatment with IL-17A inhibitors has failed is examined.
First-Time Biologic Therapy for Psoriasis and Risk for Serious Infection
The risk for serious infection in patients with psoriasis treated with biologic agents and apremilast, using etanercept as a comparator, is examined.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in Psoriasis
Loading... 
Loading...